Leuprolide
- Generic Name
- Leuprolide
- Brand Names
- Camcevi, Eligard, Fensolvi, Lupaneta Pack 1-month, Lupron, Lupron Depot-ped, Viadur, Zeulide Depot
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N16O12
- CAS Number
- 53714-56-0
- Unique Ingredient Identifier
- EFY6W0M8TG
- Background
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the...
- Indication
Leuprolide is indicated for the treatment of advanced prostate cancer and as palliative treatment of advanced prostate cancer.
It is also used for the treatment of pediatric patients with central precocious puberty (CPP).
...
- Associated Conditions
- Advanced Prostate Cancer, Anemia, Central Precocious Puberty (CPP), Endometriosis
- Associated Therapies
- Palliative Treatment
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
A 39-year-old woman with HR+, HER2+ IDC had metastatic recurrence 3 years post-mastectomy. She received THP, transitioning to HP with excellent response. Discussion focused on frontline therapy preferences for HR+, HER2+ mBC, use of endocrine therapy, and considerations for trastuzumab deruxtecan based on progression sites and patient factors.
APP Addresses Management of Abnormal Uterine Bleeding in Stem Cell Transplant
Blood transfusions are crucial for hematologic malignancy patients, but risks like iron overload exist. Abnormal uterine bleeding (AUB) in premenopausal patients undergoing hematopoietic stem cell transplantation (HSCT) increases transfusion needs. A study implemented an algorithm using leuprolide with or without OCPs to manage AUB, reducing transfusion requirements without increasing VTE risk. Oncology nurses play a key role in identifying AUB and advocating for preventive interventions.
Four Therapies That May Treat Kennedy's Disease
Clinical research for spinal-bulbar muscular atrophy (Kennedy's disease) includes phase 2 trials on exercise, clenbuterol, AJ201 (curcumin-based), and leuprorelin acetate, aiming to improve muscle strength, stamina, and quality of life.
Fathers who lost their children to gender ideology: 'I feel so betrayed'
Three fathers impacted by transgender ideology rallied at the U.S. Supreme Court, sharing stories of losing custody and parental rights due to opposing transgender medical treatments for their children. They highlighted the legal battles over these interventions and the lack of long-term research on their effects.
Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer
Eton Pharmaceuticals appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer, leveraging her extensive experience in pharmaceutical sales, marketing, and pediatric endocrinology to drive growth with upcoming product launches.
Intratumoral heterogeneity drives acquired therapy resistance in a patient with metastatic ...
A 76-year-old man with MMRd PCa showed a 99.4% PSA decline with nivolumab, but rapid resistance. Enzalutamide + nivolumab led to a 93% PSA decline. After progression, cabazitaxel, bipolar androgen therapy, enzalutamide, and nivolumab + ipilimumab failed. Biopsy of a cervical lymph node revealed MMRp PCa with BRCA2 deletion, treated with olaparib for a 63% PSA decline. ctDNA analysis showed no MSH2 or BRCA2 alterations, suggesting metastatic PCa derived from a low-grade MMRp region of the primary tumor.
Foresee Pharmaceuticals Receives the Second Positive Recommendation from DSMB to ...
Foresee Pharmaceuticals announces second positive safety review by DSMB for Casppian Phase 3 study, recommending continuation without modification. Leuprolide (FP-001) injectable emulsion shows no safety concerns in pediatric CPP patients, with almost 50% enrollment completed.
Kwality Pharma received approval for Leuprorelin Acetate for injectable suspension from Greece
Kwality Pharmaceuticals Limited (KPL) has received approval for Leuprorelin Acetate 11.25 mg vial powder and solvent for injectable suspension in Greece, entering the European market. The first three validation batches will be supplied in December, with regular supplies starting from January 2025. This CDMO arrangement is expected to generate USD 3 million annually, with plans to expand the product portfolio.
Advanced Prostate Cancer Treatment Cost Analysis and Patient Impact in the VA Healthcare System
Daniel Lee discusses VA Health Care System's patient-facing costs for advanced prostate cancer treatment, highlighting improved access via the Cleland-Dole Act, National Tele-Oncology Program, and Precision Oncology Program. Despite lower medication co-pays and annual cost caps, challenges remain, including indirect costs like travel expenses and cardiovascular risks. Lee emphasizes the need for understanding these indirect costs through patient conversations and standardized assessment tools, suggesting innovative solutions like home administration of treatments to reduce the burden on veterans.
CriteriaMapper: establishing the automatic identification of clinical trial cohorts from ...
Data from ClinicalTrials.gov, EHR (GeneDx), MSDW, and VieCure were used, covering 3.9 million patients and 79,457 de-identified patients. EC attributes from 3,475 clinical trials were analyzed, categorized into ten clinical domains, and normalized. The CriteriaMapper system includes rule-based knowledge engineering, normalization, and a clinical phenotyping knowledge base. Quality control involved verifying mappings and annotations, with evaluation using Cohen’s Kappa coefficient and precision, recall, and F1-score metrics.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath